The GOG Partners and The GOG Foundation, Inc. are thrilled to share a press release for GOG-3023 (InnovaTV 204): A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMAX®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. On September 20, 2021, Seagen and Genmab announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Leslie Randall, MD, Dianne Harris Wright Professor and Director, Division of Gynecologic Oncology, Massey Cancer Center, Virginia Commonwealth University and GOG Partners Cervical Cancer lead notes: “Tisotumab vedotin is the first antibody drug conjugate approved for cervical or any gynecologic cancer. As we develop new therapies, a diverse menu of multiple drug classes gives patients more options”
Click here to view the press release.